Research & Development: Page 77
-
PharmaVoice Team/PharmaVoice
What's New
FemmePharma Global Healthcare Inc. is devoted to developing drugs for diseases and disorders disproportionately affecting women. For more information, visit femmepharma.com. The International Society for Medical Publication Professionals (ISMPP) is a not-for-profit organization for medical public...
By PharmaVoice Team • Jan. 27, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D Trends affecting the healthcare industry U.S. Biochip Market to Reach $2.5 Billion in 2012 U.S. demand for biochip products and services is forecast to grow 9.9% annually, to $2.5 billion in 2012, led by uses in drug discovery and epidemiological research. According ...
By PharmaVoice Team • Jan. 27, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineBig Pharma Business Strategies
Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
PharmaOutlet
When it comes to making drugs safer, cheaper, and more effective, few fields have shown more promise than molecular diagnostics. But the full potential of this revolutionary area of medical research has yet to be reached, not because of technological barriers — although they do exist — but becaus...
By Peter Pitts • Jan. 27, 2009 -
PharmaVoice Team/PharmaVoice
UpFront
UpFront Milestones Almac turns 20 Dr. Robert Dunlop, president and managing director of Almac Clinical Services (left), and Sir Allen McClay, chairman of Almac Group, celebrate the division’s 20th anniversary. Almac Clinical Services, one of the key divisions at Almac Group, has grown to become t...
By PharmaVoice Team • Jan. 27, 2009 -
PharmaVoice Team/PharmaVoice
Table of Contents
ON THE COVER Partnering for Success In these times of adversity, strategic alliances become even more crucial than ever for survival. FEATURES No Pens or Mugs? No Problem. The industry is discovering it won’t lose the ability to message effectively under the new PhRMA code. The Green o...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
The Benefits of Prelaunch Access
Contributed by Natalie Douglas, CEO, IDIS Prelaunch access to drugs can provide months and perhaps years of treatment for patients with unmet medical needs when all other therapeutic options have failed or no other options are available. The benefits of named- patient programs are best realized w...
By Natalie Douglas • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
Last Word
Sirtris’ Dr. Michelle Dipp discusses maintaining corporate culture while integrating cutting-edge science and technology. Biotech business leader Michelle Dipp, M.D., Ph.D., has transitioned from a scientific background — with a medical degree and a Ph.D. — to the corporate side of the life-scien...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Alex Gorsky Sheri McCoy Johnson & Johnson Shifts Executives Global healthcare company Johnson & Johnson has appointed Alex Gorsky worldwide chairman, surgical care group, with responsibility for the surgical franchises Ethicon, Ethicon Endo-Surgery, and DePuy, as well ...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Cost Deters Cancer Patients from Seeking Treatment In addition to considerable physical and emotional burdens, cancer patients must also shoulder costly treatments resulting from their disease. A recent Thomson Reuters survey shows that the financial repercussions of cancer are taking a toll on p...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
Doctors' Choice Awards
Identifying POWERful MEDICAL ADVERTISING 6th Annual Program Generated Responses From More Than 5,700 Physicians Dusa’s ClindaReach and Pfizer’s Chantix Highest Scoring Ads ClindaReach Category: Highest-Scoring Ad (Specialist Audience) Marketer: Dusa Agency: Topin & Associates Chantix Category...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Patient Recruitment
RESEARCH & Development BY DENISE MYSHKO Patient Recruitment The Continuing Saga of Patient-Recruitment Bottlenecks If patient recruitment wasn’t already hard enough, larger, more complex trials have made the enrollment of patients even more challenging. Clinical-trial patient recruitment and ...
By Denise Myshko • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Personalized Medicine
RESEARCH & Development PERSONALIZED MEDICINE The Right Dose at the Right time BY DENISE MYSHKO Obstacles and challenges still remain to make the vision of personalized medicine a reality. Despite some early successes, the development of targeted medicines and pharmacogenomics-based testing ha...
By Denise Myshko • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Early Research
RESEARCH & Development Early Research The Future of innovation Discovery and research technologies are advancing and will have a tremendous impact on the pipelines of the future. BY DENISE MYSHKO The way new medicines are discovered is on the cusp of revolutionary change. Advances in the unde...
By Denise Myshko • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
At A Glance
Looking Forward At a GLANCE This special Year in Preview issue provides insights into the trends that will impact the industry in the coming year and beyond. Below are some highlights from the sectors covered in the following pages. Focus on specialty markets David Avitabile President JFK Communi...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Dr. Barry Goldstein Merck Appoints Head of Diabetes, Obesity Development Global pharmaceutical company Merck, Whitehouse Station, N.J., has named Barry Goldstein, M.D., Ph.D., FACP, FACE, VP of diabetes and obesity clinical development. In addition to leading overall development of co...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
CONSUMER PERSPECTIVE Consumers Wary of Therapeutic Switches Almost three quarters of prescription drug users would be very concerned if a drug they were prescribed was switched to another drug designed to treat the same condition without their doctor’s knowledge, according to a survey released by...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
eClinical Meets eLearning - Integrated eLearning Enables Efficient
16 October 2008 VIEW on ESolutions ECLINICAL Multifunction eClinical systems are becoming the norm for capturing and managing data in clinical trials. Unfortunately, the training of site staff to use these systems is still taking place in one on one sessions or at investigator meetings. The use o...
By PharmaVoice Team • Oct. 24, 2008 -
PharmaVoice Team/PharmaVoice
Where eClinical Meets Business Process
14 October 2008 VIEW on ESolutions ECLINICAL Early electronic data capture focused on finding efficiencies in data management activities, such as data entry and cleaning. When eClinical hit the mainstream, it delivered a clear view of complete trial data on a realtime basis, enabling clinical tri...
By PharmaVoice Team • Oct. 24, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
4 October 2008 VIEW on ESolutions TABLE OF CONTENTS Letter from the Editor The Forum Hitting a MobileTarget: New technologies, such as social networking and wireless mobile applications, have the potential to connect pharma with consumers, patients, and physicians more quickly and effectively tha...
By PharmaVoice Team • Oct. 24, 2008 -
PharmaVoice Team/PharmaVoice
Joe Jimenez: Straightforward and Consumer Focused
BY KIM RIBBINK COMPLETE The Package With an ability to step back from the protracted machinations that often prevail at pharma companies, is leading Novartis with a focus on the customer and a commitment to meeting goals and priorities. JOE Jimenez Sometimes it’s the simplest observations that he...
By Kim Ribbink • Sept. 30, 2008 -
PharmaVoice Team/PharmaVoice
Life After the Focus Group
BY ROBIN ROBINSON IS THE FOCUS GROUP DEAD OR JUST DECLINING? While some people say the focus group is dead, others say it will never entirely disappear. Their opinions hinge on what position they hold in the market research process and what objective the research is trying to meet (turn to page 3...
By Robin Robinson • Sept. 30, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
October 15 3rd Leadership Summit on Medicare Enrollment and PDE Data Reconciliation Hilton Old Town, Alexandria, Va. PharmaVOICE subscribers receive $300 discount; register using keycode HYU957. For more information, contact Jodi Bova, Center for Business Intelligence, at 781-939-2563, email jodi...
By PharmaVoice Team • Sept. 30, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEB BASED APPLICATIONS, SITES, AND TECHNOLOGIES inVentiv Health has relaunched The Rx Law Book, an online library that provides pharmaceutical companies with convenient, centralized access to comprehensive state and federal regulatory information pertaining to product marketing...
By PharmaVoice Team • Sept. 30, 2008 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTH CARE RELATED PRODUCTS, SERVICES, AND COMPANIES Julie Kampf has launched Career Central, a consulting firm that provides executive skill building to job seekers ranging from recent college graduates to senior level managers to professionals seeking a second or third career. Career Centr...
By PharmaVoice Team • Sept. 30, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Cubist Pharmaceuticals’ Cubicin (daptomycin), the first of the cyclic lipopeptides to gain U.S.market approval, is currently the fastest growing product in the antibiotic class, with 2007 sales surging 53% to $290.4 million. The first oxazolidinone to win U.S.Food and Drug Administration approval...
By PharmaVoice Team • Sept. 30, 2008
Previous
